AVA-Rose SRL
0.6 FTEAVA-Rose reported total assets of 381,859 € at the end of the 2025 financial year (annual accounts filed with the NBB on 01 Jul 2026), with 0.6 full-time equivalent.
The score of AVA-Rose shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
AVA-Rose's annual accounts
| 2025 | |
|---|---|
| Net result | −3,001 € |
| Equity | −2,001 € |
| Cash | 48,596 € |
| EBITDA | 20,854 € |
| Total assets | 381,859 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 01 Jul 2026
AVA-Rose's financial analysis
- Solvency-0.5%sector median: 37.8%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of AVA-Rose
AVA-Rose's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1022.725.141
- VAT number
- BE1022725141
- Peppol
- Registered · 0208:1022725141 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 25 Apr 2025
- Registered office
- 1090 Jette
- Size
- Micro · 0.6 FTE
- Latest accounts
- 2025 · filed on 01 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
AVA-Rose (SRL) has been based in Jette since 2025, active in: retail sale of pharmaceutical products. For 2025, it reports a net loss of 3,001 € and equity of −2,001 €; its revenue is not published. With 0.6 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at -0.5%, below the median of its sector (37.8%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to AVA-Rose
Companies in the same business, of comparable size and area, outside its group.
- Panax Retail sale of pharmaceutical products Wemmel · balance sheet 99,320 €
- Yascare Retail sale of pharmaceutical products Uccle · balance sheet 34,424 €
- Liwoma Retail sale of pharmaceutical products Kontich · balance sheet 289,010 €
- Farmafender Retail sale of pharmaceutical products Zedelgem · balance sheet 269,880 €
- D-Pharma Retail sale of pharmaceutical products Brasschaat · balance sheet 226,463 €
- White-to-Black Retail sale of pharmaceutical products Dilbeek · balance sheet 209,334 €
- Gerardiphar Retail sale of pharmaceutical products Bruges · balance sheet 931,701 €
- Apotheek Vanneste Tom Retail sale of pharmaceutical products Kortrijk · balance sheet €1.04m
Frequently asked questions about AVA-Rose
What is the revenue of AVA-Rose?
AVA-Rose files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of AVA-Rose?
In Belgium, the VAT number is the company number prefixed with BE: BE1022725141 for AVA-Rose, if the company is VAT-registered. Its company number (CBE) is 1022.725.141.
Where is the registered office of AVA-Rose?
According to the CBE register, the registered office of AVA-Rose is in 1090 Jette.
What is the equity of AVA-Rose?
At the close of the 2025 financial year, the equity of AVA-Rose amounts to -2,001 €, a solvency of -0.5% of total assets.
How many people work at AVA-Rose?
0.6 full-time equivalents on average according to the 2025 social balance sheet.
Who manages AVA-Rose?
The register lists 1 active mandates at AVA-Rose. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of AVA-Rose
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →